A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
An Open-Label, Single-arm, Phase I Study to Evaluate the Pharmacokinetics, Tolerability and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies
Sponsor: Zai Lab (Shanghai) Co., Ltd.
This PHASE1 trial investigates HER2 Positive Metastatic Breast Cancer and is currently completed. Zai Lab (Shanghai) Co., Ltd. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Zai Lab (Shanghai) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .